| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:09 | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma und HealthCare Royalty geben Änderung der bestehenden Lizenzvereinbarung und Beteiligung von Soleus Capital bekannt | 1.975 | EQS Group (DE) | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Bedeutende Verträge
Heidelberg Pharma und HealthCare Royalty geben Änderung der bestehenden Lizenzvereinbarung und Beteiligung von... ► Artikel lesen | |
| 07:33 | NurExone präsentiert seine Technologie international - Investoren blicken auf den nächsten Meilenstein | Small- & Micro Cap Investment | |||
| Fr | Galapagos NV: Galapagos Creates New Subscription Right Plan | 295 | GlobeNewswire (Europe) | Mechelen, Belgium; March 6, 2026, 22.01
CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,750,000 subscription rights under... ► Artikel lesen | |
| 01:06 | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Closing of its Rights Offering | 271 | GlobeNewswire (Europe) | OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) - AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development... ► Artikel lesen | |
| Fr | Tevogen Bio Inc: Letter to Shareholders from CEO Dr. Ryan Saadi | 81 | GlobeNewswire (Europe) | WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). Dear Shareholders, As we continue executing on Tevogen's long-term strategy to evolve... ► Artikel lesen | |
| 00:18 | Lisata Therapeutics, Inc.: Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. | 79 | GlobeNewswire (Europe) | Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of directors unanimously... ► Artikel lesen | |
| Fr | Harvard Bioscience, Inc.: Harvard Bioscience Announces Reverse Stock Split | 66 | GlobeNewswire (Europe) | Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| BB BIOTECH | 49,800 | 2,49 | +5,00 % | 2,25 | 23.03.2026 | |
| CSL | 88,29 | 2,60 | +2,94 % | 1,84 | 10.03.2026 | |
| AMGEN | 316,00 | 8,12 | +2,57 % | 2,52 | 13.02.2026 | |
| NOVONESIS | 48,790 | 0,87 | +1,78 % | 4,25 | 20.03.2026 | |
| GENUS | 31,000 | 0,38 | +1,23 % | 0,11 | 05.03.2026 | |
| STRYKER | 314,60 | 2,98 | +0,95 % | 0,88 | 31.03.2026 | |
| BIO-TECHNE | 48,600 | 0,27 | +0,56 % | 0,08 | 13.02.2026 | |
| BRUKER | 31,600 | 0,17 | +0,54 % | 0,05 | 23.03.2026 | |
| REGENERON PHARMACEUTICALS | 652,80 | 3,02 | +0,46 % | 0,94 | 20.02.2026 | |
| SARTORIUS STEDIM BIOTECH | 166,30 | 0,69 | +0,41 % | 0,69 | 31.03.2026 |